Tailor-made Antibodies
and Tools for Live Science
Home|||||||Technical Support|

CD19 antibody - HS-439 103

B-lymphocyte antigen
Rabbit polyclonal purified antibody
Cat. No.: HS-439 103
Amount: 50 µg
Price: $370.00
Cat. No. HS-439 103 50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Applications
 
WB: 1 : 1000 gallery  
IHC-P/FFPE: 1 : 400 gallery  
Immunogen Synthetic peptide corresponding to AA 536 to 556 from human CD19 (UniProt Id: P15391)
Epitop Epitop: AA 536 to 556 from human CD19 (UniProt Id: P15391)
Reactivity Reacts with: human (P15391).
No signal: mouse (P25918).
Other species not tested yet.
Specificity Specific for human CD19 without cross-reactivity to mouse CD19
Data sheet hs-439_103.pdf
Important information
This product belongs to the HistoSure product line of antibodies developed for and extensively tested in FFPE tissues.
For more information please visit our HistoSure brand website.
Cat. No.: HS-439 103
Amount: 50 µg
Price: $370.00
Background

CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).

Protocols